Steps in this run
| Step |
Calls |
Tokens in |
Cache hit |
Cost |
|
ranking
|
2 |
144,427 |
|
$0.81433 |
|
cluster generation
|
1 |
31,273 |
|
$0.16442 |
|
response generation
|
2 |
4,497 |
|
$0.02231 |
|
learning engine pattern analysis
|
1 |
13,556 |
|
$0.01512 |
|
haiku prescreen
|
2 |
11,703 |
|
$0.01155 |
|
learning engine self eval
|
1 |
4,608 |
|
$0.00885 |
All 9 API calls — tap to expand
31,273
Tokens in (billed)
$0.164424
Est. cost (USD)
Result preview
```json
[
{
"id": 1,
"name": "AI Clinical Decision Support, Liability & Physician Displacement",
"description": "Arguments about AI/ML tools in diagnosis, treatment recommendations, care pathways, and clinical workflow — covering adoption, accuracy, liability gaps, physician displacement, algorithmic bias, ambient scribing, and whether AI can replace or must augment clinical reasonin
$0.008952
Est. cost (USD)
Result preview
```json
[
{
"post_index": 19,
"cluster_ids": [3, 17],
"claim": "Epigenetic reprogramming entered human trials, signaling rare disease investment shift",
"argument_type": "empirical_claim",
"stance": "neutral_analysis",
"hyde_excerpt": "The FDA's clearance of the first-in-human trial for Yamanaka factor-based epigenetic reprogramming represents a watershed moment for rare
85,605
Tokens in (billed)
$0.473044
Est. cost (USD)
Result preview
```json
[
{
"post_index": 19,
"matched_article_id": 128,
"match_confidence": 85,
"match_reason": "The tweet claims ACA subsidies now cover 94% of the median enrollee's premium (just $42/month out of pocket), directly illustrating the article's core thesis that enhanced subsidies eliminate consumer price sensitivity and paradoxically fuel premium inflation by reducing demand elast
$0.009357
Est. cost (USD)
Result preview
The $42 copremium is the mechanism, not just a statistic. When enrollees have basically zero price sensitivity (and why would they, at $42?), insurers stop competing on cost and start optimizing for whatever maximizes federal reimbursement. That's the subsidy paradox I wrote about: it doesn't just mask inflation, it actively produces it.
Which raises the harder question, which is whether any amou
$0.012954
Est. cost (USD)
Result preview
The timing here matters more than most people are tracking. Life Biosciences getting FDA clearance for a first-in-human epigenetic reprogramming trial is exactly the kind of rare disease program that would have had no clean regulatory home two years ago, and that calculation just changed with the Plausible Mechanism Framework published in February 2026.
The PMF's five-element standard is almost p
$0.002601
Est. cost (USD)
Result preview
```json
[]
```
55,466
Tokens in (billed)
$0.341289
Est. cost (USD)
Result preview
```json
[]
```
$0.008850
Est. cost (USD)
Result preview
```json
[
{"post_index": 0, "prediction": "reject", "confidence": 95, "reason": "Non-English, non-healthcare content. Animal welfare anecdote unrelated to healthcare systems."},
{"post_index": 1, "prediction": "reject", "confidence": 98, "reason": "Cryptocurrency/blockchain presale promotion. No
13,556
Tokens in (billed)
$0.015121
Est. cost (USD)
Result preview
```json
[
{
"category": "ai_safety_cybersecurity_incident_tangential",
"summary": "Posts about AI security vulnerabilities, data breaches, or safety incidents that lack healthcare system context or application.",
"exclusion_rule": "Exclude posts reporting AI security incidents (Claude